These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 40965

  • 1. The effect of antipsychotic drugs on body weight: a retrospective review.
    Doss FW.
    J Clin Psychiatry; 1979 Dec; 40(12):528-30. PubMed ID: 40965
    [Abstract] [Full Text] [Related]

  • 2. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent.
    Heel RC, Brogden RN, Speight TM, Avery GS.
    Drugs; 1978 Mar; 15(3):198-217. PubMed ID: 25167
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures.
    Goodwin DG, Strobl JS, Lindsay DS.
    J Parasitol; 2011 Feb; 97(1):148-51. PubMed ID: 21348624
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
    Ereshefsky L.
    J Clin Psychiatry; 1999 Feb; 60 Suppl 10():20-30. PubMed ID: 10340684
    [Abstract] [Full Text] [Related]

  • 5. Does loxapine have "atypical" properties? Clinical evidence.
    Glazer WM.
    J Clin Psychiatry; 1999 Feb; 60 Suppl 10():42-6. PubMed ID: 10340686
    [Abstract] [Full Text] [Related]

  • 6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 7. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study.
    Hrdlicka M, Zedkova I, Blatny M, Urbanek T.
    Neuro Endocrinol Lett; 2009 Jul; 30(2):256-61. PubMed ID: 19675512
    [Abstract] [Full Text] [Related]

  • 8. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T, Kin NM, Beaulieu S, de Baptista EA.
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [Abstract] [Full Text] [Related]

  • 9. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
    Herrick-Davis K, Grinde E, Teitler M.
    J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
    [Abstract] [Full Text] [Related]

  • 10. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy.
    Huang TL, Lu CY.
    Chang Gung Med J; 2007 Oct; 30(1):26-32. PubMed ID: 17477026
    [Abstract] [Full Text] [Related]

  • 11. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC, Kennedy NM, Gribbon D.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [Abstract] [Full Text] [Related]

  • 12. Use and safety of antipsychotic drugs during pregnancy.
    Einarson A, Boskovic R.
    J Psychiatr Pract; 2009 May; 15(3):183-92. PubMed ID: 19461391
    [Abstract] [Full Text] [Related]

  • 13. Dopamine antagonism by thioridazine in schizophrenia.
    Meltzer HY, Sachar EJ, Frantz AG.
    Biol Psychiatry; 1975 Feb; 10(1):53-7. PubMed ID: 1120175
    [Abstract] [Full Text] [Related]

  • 14. Brain homovanillic acid: regional changes following chronic antipsychotic drug administration.
    Bowers MB, Rozitis A.
    Adv Biochem Psychopharmacol; 1977 Feb; 16():639-44. PubMed ID: 18907
    [No Abstract] [Full Text] [Related]

  • 15. Binding of psychotropic drugs to isolated alpha-acid glycoprotein.
    Kornguth ML, Hutchins LG, Eichelman BS.
    Biochem Pharmacol; 1981 Sep 01; 30(17):2435-41. PubMed ID: 21043242
    [Abstract] [Full Text] [Related]

  • 16. Drug interactions on spontaneous locomotor activity in rats. Neuroleptics and amphetamine-induced hyperactivity.
    Schaefer GJ, Michael RP.
    Neuropharmacology; 1984 Aug 01; 23(8):909-14. PubMed ID: 6148710
    [Abstract] [Full Text] [Related]

  • 17. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
    Tuason VB.
    J Clin Psychiatry; 1986 Mar 01; 47(3):126-9. PubMed ID: 3512535
    [Abstract] [Full Text] [Related]

  • 18. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.
    Zhang ZJ, Yao ZJ, Zhang XB, Chen JF, Sun J, Yao H, Hou G, Zhang XB.
    Acta Pharmacol Sin; 2003 Mar 01; 24(3):235-40. PubMed ID: 12617772
    [Abstract] [Full Text] [Related]

  • 19. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb 01; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 20. Weight change with atypical antipsychotics in the treatment of schizophrenia.
    Haddad P.
    J Psychopharmacol; 2005 Nov 01; 19(6 Suppl):16-27. PubMed ID: 16280334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.